Titolo	Data di pubblicazione	Autore(i)
1	Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: A combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors	2016	Kopecka, Joanna; Porto, Stefania; Lusa, Sara; Gazzano, Elena; Salzano, Giuseppina; Pinzòn-Daza, Martha Leonor; Giordano, Antonio; Desiderio, Vincenzo; Ghigo, Dario; De Rosa, Giuseppe; Caraglia, Michele; Riganti, Chiara
2	Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	2012	I. Campia; J. Kopecka; B. Castella; M. Rigoni; M. Coscia; A. Bosia; D. Ghigo; M. Massaia; C. Riganti
3	Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells	2013	C. Riganti; B. Castella; J. Kopecka; I. Campia; M. Coscia; G. Pescarmona; A. Bosia; D. Ghigo; M. Massaia
4	Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway	2010	Coscia M; Quaglino E; Iezzi M; Curcio C; Pantaleoni F; Riganti C; Holen I; Mönkkönen H; Boccadoro M; Forni G; Musiani P; Bosia A; Cavallo F; Massaia M
5	Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.	2010	Moriceau G; Ory B; Mitrofan L; Riganti C; Blanchard F; Brion R; Charrier C; Battaglia S; Pilet P; Denis M; Shultz LD; Mönkkönen J; Redini F; Heymann D
6	Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma	2015	IC Salaroglio; I Campia; J Kopecka; E Gazzano; S Orecchia; D Ghigo; C Riganti
7	Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5	Being printed	Milosevic V.; Kopecka J.; Salaroglio I.C.; Libener R.; Napoli F.; Izzo S.; Orecchia S.; Ananthanarayanan P.; Bironzo P.; Grosso F.; Tabbo F.; Comunanza V.; Alexa-Stratulat T.; Bussolino F.; Righi L.; Novello S.; Scagliotti G.V.; Riganti C.
8	What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg	2019	Alexa-Stratulat T.; Pesic M.; Gasparovic A.C.; Trougakos I.P.; Riganti C.
9	Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression	2018	Barbara Castella, Myriam Foglietta, Chiara Riganti, Massimo Massaia
10	Vγ9Vδ2 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma	2018	Barbara Castella, Assunta Melaccio, Myriam Foglietta, Chiara Riganti, Massimo Massaia
11	Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells	2019	Salaroglio, Iris Chiara; Abate, Carmen; Rolando, Barbara; Battaglia, Luigi; Gazzano, Elena; Colombino, Elena; Costamagna, Costanzo; Annovazzi, Laura; Mellai, Marta; Berardi, Francesco; Capucchio, Maria Teresa; Schiffer, Davide; Riganti, Chiara
12	Two repeated low doses of doxorubicin are more effective than one single high dose against tumors overexpressing P-glycoprotein	2015	C. Riganti; E. Gazzano; GR. Gulino; M. Volante; D. Ghigo; J. Kopecka
13	Tuning the Hydrophobicity of a Mitochondria-Targeted NO Photodonor	2018	Sodano, Federica; Rolando, Barbara; Spyrakis, Francesca; Failla, Mariacristina; Lazzarato, Loretta*; Gazzano, Elena; Riganti, Chiara; Fruttero, Roberta; Gasco, Alberto; Sortino, Salvatore
14	“Three-bullets” loaded mesoporous silica nanoparticles for combined photo/chemotherapy	2019	Tessaro A.L.; Fraix A.; Da Silva A.C.P.; Gazzano E.; Riganti C.; Sortino S.
15	The “LDL-masked doxorubicin”: an effective strategy for drug delivery across hypoxic blood brain barrier	2014	ML Pinzòn-Daza; J Kopecka; I Campia; R Garzon; C Riganti
16	THE SURVIVAL OF TUMOR CELLS IN IGVH UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA IS HIGHLY DEPENDENT ON EXOGENOUS SIGNALS DELIVERED BY THE TUMOR MICROENVIRONMENT	2009	Coscia M; Pantaleoni F; Riganti C; Rigoni M; Vitale C; Peola S; Drandi D; Ladetto M; Bosia A; Boccadoro M; Massaia M.
17	The Role of C/EBP-β LIP in Multidrug Resistance	2015	C. Riganti; J. Kopecka; E. Panada; S. Barak; M. Rubinstein
18	The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress	2008	RIGANTI C; COSTAMAGNA C; DOUBLIER S; MIRAGLIA E; POLIMENI M; BOSIA A; GHIGO D
19	The NADPH oxidase inhibitor apocynin (acetovanillone) induces oxidative stress	2006	RIGANTI C; COSTAMAGNA C; BOSIA A; GHIGO D
20	The mevalonate pathway as a metabolic target to circumvent multidrug-resistance in chronic lymphocytic leukemia cells (CLL)	2012	Micol Rigoni; Marta Coscia; Chiara Riganti; Ivana Campia; Silvia Peola; Barbara Castella; Valentina Griggio; Francesca Pantaleoni; Patrizia Sciancalepore; Daniela Drandi; Marco Ladetto; Amalia Bosia; Mario Boccadoro; Massimo Massaia